Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alessandro Rambaldi, MD
Myeloproliferative Disorders-Research Consortium
Principal Investigator - Ellen Ritchie, MD
Myeloproliferative Disorders-Research Consortium
Principal Investigator - John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ospedale Riuniti de Bergamo
Bergamo, Italy, Italy
- University of Florence
Florence, Italy, Italy
- Ospedale San Maartino Genova
Genova, Italy, Italy
- San Matteo Hospital
Pavia, Italy, Italy
- Universita Cattolica del Sacro Cuore
Rome, Italy, Italy
- Mayo Clinic
Scottsdale, Arizona, United States
- the Palo Alto Clinic
Palo Alto, California, United States
- Georgetown University Medical Center
Washington D.C., District of Columbia, United States
- Emory Hospital
Atlanta, Georgia, United States
- John H. Stroger Hospital of Cook County
Chicago, Illinois, United States
- University of Illinois at Chicago
Chicago, Illinois, United States
- University of Kansas Cancer Center
Westwood, Kansas, United States
- University of Maryland
Baltimore, Maryland, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Weill Cornell Medical College
New York, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
- Geisinger Cancer Center
Danville, Pennsylvania, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- University of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2011
- Primary completion
- 31 Dec 2016
- Completion
- 31 Dec 2016
- Last update posted
- 11 Jan 2017
- Registered enrollment
- 135
- Registry id
- NCT01259817
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.